Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by C10H12N2on Jan 27, 2023 3:37pm

121 Views

Post# 35250944

All Roads Lead To Dante's Inferno @ Algernon Pharmaceuticals

Take a look at the performance of Xortx Therapeutics (XRTX) today with its recent move towards a Phase III clinical trial. They're now at 52 week low with no bottom. The relevance is Xortx's recently resigned CEO is the sole member of Algernon Pharmaceuticals "Business Advisory Board".

Business Advisory Board - Algernon Pharmaceuticals